Valneva Nears Critical Support as Revenue Slump Deepens and Cost-Cutting Accelerates

Valneva shares plunge nearly 40% in 2024 as Q1 revenue drops 37%; AGM on June 25 may decide fate amid cost cuts and Lyme vaccine hopes.

The French vaccine maker Valneva is heading into its annual general meeting under a cloud of operational distress and technical vulnerability. Shares have lost nearly 40% since the start of the year, and with the stock trading at €2.30–€2.32, the distance to the 52-week low of €2.13 has shrunk to less than 8%. The AGM, scheduled for 25 June in Lyon, could either offer a lifeline of clarity or deepen the sense of crisis.

The trigger for the selling pressure was a dire first-quarter report. Revenues collapsed by 37% year-on-year, dragging the company to a net loss of €32.1 million. The travel vaccine business, a core revenue driver, has softened markedly. In response, management has unveiled a sweeping restructuring plan: 10–15% of the global workforce will be cut, and operating expenses are set to fall by as much as a third. Yet the market has so far shrugged off the belt-tightening, with the stock continuing its slide.

Valneva’s full-year outlook now looks significantly weaker. The board expects 2026 revenue in a range of €135 million to €150 million, a downward revision that reflects, among other factors, softer sales of third-party products. The market capitalisation has shrunk to around €445 million.

Analyst opinion remains fractured. Goldman Sachs adopted a sell stance in April, while First Berlin reiterated a buy recommendation at the end of May. The divergence underscores the uncertainty surrounding Valneva’s ability to stabilise its commercial operations and deliver on its pipeline, notably the Lyme disease vaccine candidate developed jointly with Pfizer, which the company plans to showcase at investor conferences in Europe and the US this month.

Technically, the picture is precarious. The stock is well below both the 50-day moving average of €2.54 (a gap of 9.4%) and the 200-day line at €3.73 (a 38% shortfall). The relative strength index stands at 37–38, approaching but not yet in oversold territory. A break below the €2.13 floor would confirm the downtrend and likely trigger further selling. Conversely, reclaiming the 50-day average could offer the first sign of relief.

The broader market environment offers little help. The STOXX Europe 600 fell to a two-week low on Monday, and the oil price surged more than 4% amid escalating tensions in the Middle East. For small-cap biotech stocks like Valneva, a risk-off shift is especially punishing — investors become less willing to finance long R&D cycles when visibility on near-term returns is low.

With the AGM documents released on 4 June, all eyes are now on Lyon. Management will face shareholders’ questions on the reduced revenue guidance and the path to a commercial recovery. After a 40% rout, routine communication will no longer suffice. The market wants hard evidence that the cost cuts and pipeline progress can halt the slide.